Ashley Jones
Charlotte, NCNPI 1376145045
Payments from drug & device makers
Across 216 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ardelyx, Inc.$663
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$588
- Gilead$444
- Takeda Pharmaceuticals U.S.A., Inc.$385
- AbbVie$353
- Madrigal Pharmaceuticals$298
- plus $2K from 18 others
What the payments were for
- Food & beverage$4,28998%
- Education$792%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ardelyx, Inc. | 38 | $663 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 31 | $588 |
| Gilead | 22 | $444 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $385 |
| AbbVie | 17 | $353 |
| Madrigal Pharmaceuticals | 12 | $298 |
| Johnson & Johnson | 8 | $212 |
| Sanofi | 8 | $198 |
| Phathom Pharmaceuticals, Inc. | 9 | $181 |
| Ironwood Pharmaceuticals, Inc | 10 | $165 |
| Lilly USA, LLC | 8 | $150 |
| Regeneron Healthcare Solutions, Inc. | 6 | $145 |
| AstraZeneca | 6 | $97 |
| Redhill Biopharma Inc. | 4 | $82 |
| Aimmune Therapeutics, Inc. | 3 | $80 |
| Braintree Laboratories, Inc. | 3 | $70 |
| Celltrion USA Inc. | 3 | $70 |
| Novo Nordisk | 2 | $34 |
| Intercept Pharmaceuticals, Inc. | 2 | $33 |
| Bristol Myers Squibb | 2 | $30 |
| Ferring Pharmaceuticals Inc. | 2 | $29 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $16 |
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 76 | $72,205 |
| IbsrelaTenapanor Hcl | 33 | $71,539 |
| CreonLipase/Protease/Amylase | 13 | $32,746 |
| Dexlansoprazole DrDexlansoprazole | 21 | $7,052 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 101 | $6,697 |
| Sucralfate | 11 | $1,546 |
| Entecavir | 14 | $1,238 |
| Pantoprazole Sodium | 131 | $839 |
| Dicyclomine Hcl | 48 | $763 |
| Ondansetron Hcl | 28 | $584 |
| Omeprazole | 39 | $460 |
| Ondansetron OdtOndansetron | 19 | $402 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 17 | $342 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 20 | $262 |
| Esomeprazole Magnesium | 20 | $249 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $353 | $104,95189 claims |
| Ardelyx, Inc.Ibsrela | $663 | $71,53933 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in North Carolinaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.